In Brief: U.S. Surgical/EndoTex
This article was originally published in The Gray Sheet
Executive SummaryU.S. Surgical/EndoTex: Agreement gives USSC a 90-day option to acquire EndoTex Interventional Systems' technology relating to covered stent, stent graft and "related delivery system technology" for abdominal aortic aneurysms (AAA) and AV fistula applications, USSC says. Following due diligence by USSC, the firm will either "consummate the transaction or convert its initial payment into an equity investment," at the end of the 90-day period. Menlo Park, California-base EndoTex expects to begin clinical trials in the third quarter "in conjunction" with USSC, evaluating the covered stent in AAA and aneurysm repair...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.